Home » Stocks » NeuBase Therapeutics

NeuBase Therapeutics, Inc. (NBSE)

Stock Price: $8.76 USD 0.10 (1.15%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 202.55M
Revenue (ttm) n/a
Net Income (ttm) -36.47M
Shares Out 23.12M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $8.76
Previous Close $8.66
Change ($) 0.10
Change (%) 1.15%
Day's Open 8.72
Day's Range 8.51 - 8.86
Day's Volume 84,171
52-Week Range 4.15 - 11.78

More Stats

Market Cap 202.55M
Enterprise Value 166.95M
Earnings Date (est) Jan 14, 2021
Ex-Dividend Date n/a
Shares Outstanding 23.12M
Float 17.10M
EPS (basic) -2.84
EPS (diluted) -3.26
FCF / Share -0.40
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.32M
Short Ratio 4.79
Short % of Float 7.73%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.77
Revenue n/a
Operating Income -35.10M
Net Income -36.47M
Free Cash Flow -8.55M
Net Cash 35.60M
Net Cash / Share 1.54
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC 3,944.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$15.67*
(78.88% upside)
Low
13.0
Current: $8.76
High
18.0
Target: 15.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-26.34-15.13-23.85-25.31-17.81-9.12-4.62-3.29-1.24-1.02
Net Income-26.96-13.24-23.81-25.77-15.20-9.13-5.65-1.45-5.100.49
Shares Outstanding8.272.822.241.571.421.110.940.710.640.55
Earnings Per Share-3.26-4.60-10.60-16.40-10.80-8.20-6.00-2.00-7.801.20
Operating Cash Flow-2.85-9.49-19.29-15.99-10.69-5.36-2.69-1.75-1.00-0.52
Capital Expenditures-0.460.530.09-0.01-0.18---0.030.07-0.03
Free Cash Flow-3.30-8.96-19.20-16.00-10.88-5.36-2.69-1.79-0.93-0.55
Cash & Equivalents10.310.2512.8012.5528.7013.225.122.630.470.42
Total Debt0.120.250.110.090.050.040.010.02-0.07
Net Cash / Debt10.190.0012.6912.4628.6513.185.112.610.470.35
Assets12.530.2527.9329.4546.3732.035.743.521.411.41
Liabilities2.500.295.084.483.885.270.481.096.191.79
Book Value10.03-0.0422.8424.9642.4926.755.262.43-4.78-0.38
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NeuBase Therapeutics, Inc.
Country United States
Employees 15
CEO Dietrich A. Stephan

Stock Information

Ticker Symbol NBSE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NBSE

Description

NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.